인슐린 시장 : 약제, 유형, 용도별 - 세계 예측(2025-2030년)

The Insulin Market was valued at USD 43.64 billion in 2023, expected to reach USD 46.76 billion in 2024, and is projected to grow at a CAGR of 7.63%, to USD 73.03 billion by 2030.

Insulin, a crucial hormone for diabetes management, is central to both Type 1 and Type 2 diabetes treatments. The market scope for insulin revolves around pharmaceuticals, biosimilars, and advanced delivery systems. The necessity of insulin is driven by the rising global prevalence of diabetes, lifestyle changes, and increasing obesity rates. Major applications include injectable insulin formulations, insulin pumps, and emerging non-invasive delivery mechanisms. Insulin's end-use scope spans hospitals, clinics, and homecare settings, catering to diverse patient demographics.

Key market growth influencers include technological advancements in insulin delivery systems, increased government initiatives for diabetes management, and enhanced healthcare infrastructure in emerging economies. Rising awareness about diabetes care and the advantages of insulin therapy further stimulate market expansion. Potential opportunities lie in developing innovative delivery methods, like inhalable insulin or smart insulin pens, and leveraging artificial intelligence for personalized insulin therapy. Companies can capitalize on these trends by investing in research and development to create user-friendly, efficient insulin delivery solutions and collaborate with healthcare providers to improve patient outcomes.

However, the market faces challenges such as high insulin costs, stringent regulatory frameworks, and competition from alternative diabetes treatments like oral medications and lifestyle management programs. Limitations include potential side effects and the necessity for constant monitoring and dose adjustments. Innovative areas ripe for exploration include biosimilar insulin products, advancements in artificial pancreas systems, and exploration of gene therapy for long-term diabetes management.

The insulin market presents a dynamic environment with substantial growth potential. Companies should focus on technological integration, cost-effective solutions, and expanding access to insulin in under-served regions. As the healthcare landscape evolves, aligning with patient-centric approaches and utilizing predictive analytics for disease management can offer significant competitive advantages and foster sustainable business growth in the insulin market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Insulin Market

The Insulin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence of diabetes and obesity with increasing geriatric population
  • Rapid development in insulin delivery systems
  • Favorable reimbursement policies for insulin products in developed countries
• Market Restraints
  • High cost associated with insulin drugs
• Market Opportunities
  • Potential investments in R&D activities for insulin development
  • Rising approvals for interchangeable biosimilar insulin products
• Market Challenges
  • Complex regulatory landscape and problems related to patient adherence to treatment regimens

Porter's Five Forces: A Strategic Tool for Navigating the Insulin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Insulin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Insulin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Insulin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Insulin Market

A detailed market share analysis in the Insulin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Insulin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Insulin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Insulin Market, highlighting leading vendors and their innovative profiles. These include ADOCIA, AstraZeneca PLC, Baxter International, Inc., Biocon Limited, Bioton S.A., CardioVends, Eli Lilly and Company, Eva Pharma, GeneSys Biologics, Glenmark Pharmaceuticals Ltd., Gulf Pharmaceutical Industries (Julphar), MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., Wockhardt Limited, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Insulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across Biologic and Biosimilar.
• Based on Type, market is studied across Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin, Rapid-acting Insulin, and Short-acting Insulin.
• Based on Application, market is studied across Type I Diabetes and Type II Diabetes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of diabetes and obesity with increasing geriatric population
    • 5.1.1.2. Rapid development in insulin delivery systems
    • 5.1.1.3. Favorable reimbursement policies for insulin products in developed countries
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with insulin drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Potential investments in R&D activities for insulin development
    • 5.1.3.2. Rising approvals for interchangeable biosimilar insulin products
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory landscape and problems related to patient adherence to treatment regimens
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features
  • 5.2.2. Type: Long-acting insulins provide basal coverage for an extended duration
  • 5.2.3. Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Insulin Market, by Drug

• 6.1. Introduction
• 6.2. Biologic
• 6.3. Biosimilar

7. Insulin Market, by Type

• 7.1. Introduction
• 7.2. Intermediate-acting Insulin
• 7.3. Long-acting Insulin
• 7.4. Premixed Insulin
• 7.5. Rapid-acting Insulin
• 7.6. Short-acting Insulin

8. Insulin Market, by Application

• 8.1. Introduction
• 8.2. Type I Diabetes
• 8.3. Type II Diabetes

9. Americas Insulin Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Insulin Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Insulin Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Sanofi Eyes USD 1.6 Billion Investment in German Insulin Facility to Boost Production
  • 12.3.2. Arecor and Medtronic Diabetes Collaborate to Develop Thermostable Insulin for Implantable Pumps
  • 12.3.3. Eris Lifesciences Acquires India branded Formulation Business of Biocon Biologics
  • 12.3.4. Insulin Maker GeneSys to Invest USD 50-60 MN to Set Up Plant in Hyderabad
  • 12.3.5. Gulf Pharmaceutical Industries 'Julphar' Signs Landmark Agreement with Sunshine Lake Pharma to Pioneer Insulin Biosimilar Manufacturing in MENA
  • 12.3.6. Sanofi Launches New Long-Acting Insulin Drug in India
  • 12.3.7. California, Drugmaker Partner to Produce Affordable Insulin
  • 12.3.8. Novo Nordisk to Launch Once-a-Week Insulin Regime for Indian Patients
  • 12.3.9. ADOCIA Announces the Successful Phase 1 Study for BioChaperone Lispro with Partner Tonghua Dongbao
  • 12.3.10. Glenmark Launches Type 2 Diabetes and High Insulin Resistance Drug in India; Shares Jump
  • 12.3.11. Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
  • 12.3.12. Novo Nordisk Launches Unbranded Biologic of Tresiba Analog Insulin to Expand Affordability Options for Patients
  • 12.3.13. Optum, Sanofi Partner on Low Cost Insulin for the Uninsured

Companies Mentioned

• 1. ADOCIA
• 2. AstraZeneca PLC
• 3. Baxter International, Inc.
• 4. Biocon Limited
• 5. Bioton S.A.
• 6. CardioVends
• 7. Eli Lilly and Company
• 8. Eva Pharma
• 9. GeneSys Biologics
• 10. Glenmark Pharmaceuticals Ltd.
• 11. Gulf Pharmaceutical Industries (Julphar)
• 12. MannKind Corporation
• 13. Merck & Co., Inc.
• 14. MJ Biopharm Pvt. Ltd.
• 15. Novartis AG
• 16. Novo Nordisk A/S
• 17. Oramed Pharmaceuticals Inc.
• 18. Pfizer Inc.
• 19. Sanofi S.A.
• 20. Tonghua Dongbao Pharmaceutical Co., Ltd.
• 21. Viatris Inc.
• 22. Wockhardt Limited
• 23. Zealand Pharma A/S